NCT06501521 Non-invasive Brain Tumor Molecular Diagnostics and Monitoring
| NCT ID | NCT06501521 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Institute of Molecular and Translational Medicine, Czech Republic |
| Condition | Brain Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2020-01-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2020-01-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective multicenter study aims to enroll GBM patients who will undergo repeated assessments (preoperatively and 3 months post-surgery) to detect circulating tumor cells and analyze the transcriptomic profiles of EVs in their blood. The prognostic and monitoring significance of these biomarkers to disease course (assessing treatment efficacy, resistance incidence, tumor progression) will be evaluated. Concurrently, proteomic profiles typical of GBM will be analyzed in blood and ocular secretion samples from GBM patients, patients with low-grade gliomas, and patients without brain tumors to identify and validate novel protein biomarkers suitable for disease monitoring. Additionally, this study proposes an innovative approach to monitor GBM patients by investigating the presence of GBM-specific nucleic acid fragments in urine.
Eligibility Criteria
Inclusion Criteria: Adult patients with brain tumors - Exclusion Criteria: No other cancer; no inflammatory disease \-
Contact & Investigator
Marian Hajduch, MD,PhD
PRINCIPAL INVESTIGATOR
Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
Frequently Asked Questions
Who can join the NCT06501521 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Brain Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06501521 currently recruiting?
Yes, NCT06501521 is actively recruiting participants. Contact the research team at josef.srovnal@upol.cz for enrollment information.
Where is the NCT06501521 trial being conducted?
This trial is being conducted at Olomouc, Czechia.
Who is sponsoring the NCT06501521 clinical trial?
NCT06501521 is sponsored by The Institute of Molecular and Translational Medicine, Czech Republic. The principal investigator is Marian Hajduch, MD,PhD at Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic. The trial plans to enroll 200 participants.